AbbVie (NYSE:ABBV) Issues FY25 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY25 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $11.99-12.19 for the period, compared to the consensus estimate of $12.30. AbbVie also updated its Q1 guidance to $2.34-2.38 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ABBV shares. Piper Sandler Companies restated an “overweight” rating and set a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Erste Group Bank raised AbbVie to a “strong-buy” rating in a research report on Monday, March 17th. Daiwa America lowered AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 5th. Piper Sandler upped their target price on AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Guggenheim lifted their price target on shares of AbbVie from $212.00 to $214.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $211.45.

AbbVie Stock Down 1.9 %

AbbVie stock traded down $3.88 during mid-day trading on Thursday, reaching $201.31. The stock had a trading volume of 7,582,383 shares, compared to its average volume of 5,769,384. AbbVie has a one year low of $153.58 and a one year high of $218.66. The company has a 50-day moving average price of $199.66 and a two-hundred day moving average price of $189.22. The company has a market capitalization of $356.11 billion, a price-to-earnings ratio of 83.88, a PEG ratio of 1.62 and a beta of 0.61. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the previous year, the firm posted $2.79 earnings per share. On average, analysts expect that AbbVie will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.26%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s dividend payout ratio is currently 273.33%.

Insiders Place Their Bets

In other news, SVP Kevin K. Buckbee sold 18,944 shares of AbbVie stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the transaction, the senior vice president now owns 11,496 shares in the company, valued at $2,338,401.36. This trade represents a 62.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at approximately $11,183,398.72. This represents a 52.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,471 shares of company stock valued at $23,426,451. Company insiders own 0.08% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AbbVie stock. Revolve Wealth Partners LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 72.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,279 shares of the company’s stock after purchasing an additional 3,064 shares during the quarter. Revolve Wealth Partners LLC’s holdings in AbbVie were worth $1,294,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.